The RTW Podcast Titelbild

The RTW Podcast

The RTW Podcast

Von: RTW Investments LP
Jetzt kostenlos hören, ohne Abo

Nur 0,99 € pro Monat für die ersten 3 Monate

Danach 9.95 € pro Monat. Bedingungen gelten.

Über diesen Titel

We’re witnessing a healthcare revolution, as medical and science innovations transform the lives of millions. Join as we speak to bright scientific minds, inspiring company founders and healthcare champions that are driving this exciting period of scientific discovery.

Subscribe to catch each episode as it goes live.

The content of this podcast does not constitute investment advice, an offer to provide investment advisory services, or an offer to sell or solicitation of an offer to buy an interest in any investment fund.

RTW Investments, LP 2023
Persönliche Finanzen Wissenschaft Ökonomie
  • Biotech’s Next Era: Innovation and Commercialization
    Jan 12 2026

    Rod Wong joins Stephanie Sirota to trace biotech's evolution. What forces built today’s innovation landscape, and what might the next decade reveal?

    PODCAST TEAM

    Producer & Director: Devon Leaver

    Editor: Dominique Guerra

    Production Coordinator: YingYu Lin

    Production Support: Annabelle Chan

    Theme music: Ganymede by Yehezkel Raz

    Additional music: APM Music

    Featuring: Rod Wong, Managing Partner and Chief Investment Officer at RTW Investments, moderated by Stephanie A. Sirota, Partner, Chief Business Officer at RTW Investments.

    FOLLOW US

    Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

    To make sure you never miss an episode, you can subscribe to the RTW podcast on YouTube, Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

    Learn more about 'Innovation is the Best Medicine' here.

    CHAPTERS

    00:00 – Introduction

    1:22 – Gene therapy and biotech

    4:51 – Rod Wong’s journey into biotech

    9:55 – Rod Wong: Investor or Business Builder?

    12:43 – Growing trends in biotechnology

    15:36 – Generating Alpha in Biotech

    21:54 – Looking forward for RTW

    23:51 - Outro

    DISCLAIMER

    This interview was given by Rod Wong, Managing Partner and Chief Investment Officer at RTW Investments, and moderated by Stephanie A. Sirota, Partner, Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.

    Mehr anzeigen Weniger anzeigen
    25 Min.
  • The Split Vote: UroGen and the FDA
    Dec 1 2025

    When an FDA panel held her company’s future in the balance, UroGen Pharma CEO Liz Barrett refused to fold, even with the odds stacked, a plunging stock, and one vote deciding it all.

    PODCAST TEAM

    Producer and Director: Devon Leaver

    Editor: Dominique Guerra

    Production Coordinator: YingYu Lin

    Production Support: Annabelle Chan

    Story Consultants: Partner & Research Analyst Tony Nguyen, and Chief Corporate Finance Officer, Chris Seiter.

    Featuring: Liz Barrett, President & CEO of UroGen Pharma, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP.

    FOLLOW US

    Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

    To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

    CHAPTERS

    00:00 - Introduction

    00:54 – Liz Barrett’s pharma journey

    03:26 - UroGen: the product and the pipeline

    08:31 - The FDA vote on UroGen

    15:07 - UroGen and RTW’s relationship

    18:42 - Liz Barrett’s leadership style

    22:40 - Outro

    DISCLAIMER

    This interview was given by Liz Barrett, President & CEO of UroGen Pharma, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.

    Mehr anzeigen Weniger anzeigen
    24 Min.
  • 14 Months to Treatment: Breaking Records in Rare Disease Therapy
    Oct 6 2025

    From a Thanksgiving night emergency to one of the fastest gene therapies ever deployed, this is the story of a family’s relentless pursuit to help their daughter, and how RTW Foundation made it possible.

    This episode was recorded on June 11, 2025, and the clinical trial details discussed may have changed; please see ellysteam.org for the most current information on Elly’s case.

    PODCAST TEAM

    Producer & Director: Devon Leaver

    Production Coordinator: YingYu Lin

    Editor: Dominique Guerra

    Research Consultants: Joe Katakowski, PhD, and Nicole Litt

    Story Consultant: Samantha Darris

    Theme music: Ganymede by Yehezkel Raz

    Additional music: APM Music

    Featuring: Michelle Krueger, Managing Director at Alvarez & Marsal Transaction Advisory Group, and the co-founder of Elly’s Team, moderated by Stephanie A. Sirota, Partner, Chief Business Officer at RTW Investments, LP.

    FOLLOW US

    Now you can follow along in the format you prefer. Watch the video feed of this podcast on YouTube or read the transcript at rtwfunds.com/podcasts.

    To make sure you never miss an episode, you can subscribe wherever you get your podcasts. Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

    CHAPTERS

    00:00 - Introduction

    01:16 – Elly’s Diagnosis

    04:37 - Finding a treatment with RTW Foundation

    09:42 - Elly’s journey: from research to treatment

    14:50 - Becoming the first child to receive an IRF2BPL gene replacement therapy

    17:17 - Expanding the clinical trial for NEDAMSS

    19:12 - How to improve drug research and development

    21:18 - Outro and disclaimer

    DISCLAIMER

    This interview was given by Michelle Krueger, Managing Director at Alvarez & Marsal Transaction Advisory Group, and the co-founder of Elly’s Team, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.

    Mehr anzeigen Weniger anzeigen
    22 Min.
Noch keine Rezensionen vorhanden